Patented Medicine Prices Review Board Canada
A Patented Medicine Prices Review Board (PMPRB) Hearing Panel has issued an order relating to the medicine Procysbi, manufactured and marketed in Canada by Horizon Therapeutics Canada.
On September 1, 2022, the Hearing Panel issued a decision that found that the price of Procysbi was excessive under section 83 and 85 of the Patent Act. In an order dated October 13, 2022, the Hearing Panel directed Horizon to pay $22,028,977.26 to the Receiver General of Canada within 30 days of the date of the Order. It is the largest amount ever ordered by the Board in an excessive price hearing. The Board has also ordered that the ceiling price of Procysbi be reduced to a non-excessive level.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
